Researchers at Cincinnati Children’s Hospital Medical Center in the US have designed and tested a new computerised solution which uses artificial intelligence (AI) to effectively identify eligible participants from electronic health records (EHRs).
The study, conducted in the Emergency Department, demonstrated that automated patient screening eases enrolment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new technology allows busy clinical staff to focus their time on evaluating the high priority candidates eligible for trials.
It is reported that the technology would improve patient recruitment for clinical trials.
The research revealed that Automated Clinical Trial Eligibility Screener (ACTES) system reduced patient screening time by 34% and improved patient enrolment by 11.1%.
Additionally, ACTES improved the number of patients screened by 14.7% and those approached by 11.1%.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe natural language processing of the system enables computers to understand human language as the system analyses large amounts of linguistic data.
This makes it possible for computer programmes to interpret and generate knowledge independently.
The machine learning component of the system also allows it to study historical enrolments to improve future recommendations, the researchers said.
Cincinnati Children’s Hospital Medical Center Division of Biomedical Informatics faculty member Yizhao Ni said: “Because of the large volume of data documented in EHRs, the recruiting processes used now to find relevant information are very labor intensive within the short time frame needed.
“By leveraging natural language processing and machine learning technologies, ACTES was able to quickly analyse different types of data and automatically determine patients’ suitability for clinical trials.”
The study was supported by funding from National Institutes of Health (1R01LM012230, 1U01HG008666, 5U18DP006134), Agency for Healthcare Research and Quality (1R21HS024983), and from Cincinnati Children’s Hospital Medical Centre.
